| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| I408285-1ml | 1ml | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $249.90 |
Topo II Selective Inhibitors | Activators
| Specifications & Purity | 10mM in DMSO |
|---|---|
| Storage Temp | Store at -80°C |
| Shipped In | Dry ice |
| Product Description | Information Idarubicin HCl (4-demethoxydaunorubicin, NSC256439, 4-DMDR) is a hydrochloride salt form of Idarubicin which is an anthracycline antibiotic and aDNA topoisomerase II (topo II)inhibitor for MCF-7 cells with IC50 of 3.3 ng/mL in a cell-free assay. Idarubici Idarubicin has significant cytotoxic activity against multicellular spheroids, comparable to the antiproliferative effects on monolayer cells. Idarubicin inhibits CYP450 2D6. Idarubicin is about 57.5-fold and 25-fold more active than doxorubicin and epirubicin, respectively. Idarubicin is able to overcome P-glycoprotein-mediated multidrug resistance. Idarubicin inhibits PMN superoxide radical formation. Idarubicin could be coupled to the monoclonal antibodies (anti-Ly-2.1, anti-L3T4, or anti-Thy-1) with retention of protein solubility and antibody activity. Idarubicin inhibits the proliferation of NALM-6 cells with an IC50 of 12 nM. In vivo Reduction of Idarubicin is dependent upon ketone reductases, and proceeds more stereoselectively than that of most ketones giving rise to the (13S)-epimer almost exclusively. The high stereospecificity in Idarubicin reduction might result from chiral induction due to the presence of asymmetric centres near to the carbonyl group in Idarubicin. cell lines： Concentrations：0.1 nM-10 μM Incubation Time：24 hours Powder Purity:≥99% |
| Molecular Weight | 533.95 |
|---|
Enter Lot Number to search for COA:
| Solubility | Solubility (25°C) In vitro DMSO: 46 mg/mL (198.09 mM); Ethanol: 6 mg/mL (25.83 mM); Water: Insoluble; |
|---|
